LENZ Therapeutics, Inc.
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
LENZ | US
Overview
Corporate Details
- ISIN(s):
- US38870X1046 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 201 LOMAS SANTA FE DRIVE, SUITE 300, 92075 SOLANA BEACH
- Website:
- https://lenz-tx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
LENZ Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmic therapies to improve vision. The company's lead product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, a prescription eye drop for the treatment of presbyopia, the age-related loss of near vision. According to the company, VIZZ is the first FDA-approved aceclidine-based therapy for this condition, targeting a significant market of approximately 128 million people in the United States and 1.8 billion globally. LENZ Therapeutics aims to provide a best-in-class pharmaceutical solution that offers freedom from reading glasses for a broad patient population.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all LENZ Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for LENZ Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for LENZ Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
